214 related articles for article (PubMed ID: 32839900)
1. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
Verdial FC; Mamtani A; Pawloski KR; Sevilimedu V; D'Alfonso TM; Zhang H; Gemignani ML; Barrio AV; Morrow M; Tadros AB
Ann Surg Oncol; 2022 Jun; 29(6):3810-3819. PubMed ID: 35246810
[TBL] [Abstract][Full Text] [Related]
3. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
4. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV
Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.
Boughey JC; Hoskin TL; Goetz MP
Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077
[TBL] [Abstract][Full Text] [Related]
6. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
[TBL] [Abstract][Full Text] [Related]
8. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals?
Williams AD; Dang CT; Sevilimedu V; Morrow M; Barrio AV
Ann Surg Oncol; 2022 Dec; 29(13):8002-8011. PubMed ID: 35871672
[TBL] [Abstract][Full Text] [Related]
10. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy.
Botty Van den Bruele A; Lavery J; Plitas G; Pilewskie ML
Ann Surg Oncol; 2021 Feb; 28(2):968-974. PubMed ID: 32813202
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer.
Montagna G; Tong Y; Ritter M; Levi J; Weber WP; Chen X; Shen K
Oncology; 2021; 99(6):359-364. PubMed ID: 33735903
[TBL] [Abstract][Full Text] [Related]
12. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
[TBL] [Abstract][Full Text] [Related]
13. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
15. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?
Cerbelli B; Botticelli A; Pisano A; Campagna D; De Vincentiis L; Pernazza A; Frusone F; Scavina P; Monti M; Fortunato L; Costarelli L; d'Amati G
Breast J; 2019 Mar; 25(2):273-277. PubMed ID: 30734420
[TBL] [Abstract][Full Text] [Related]
19. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
[TBL] [Abstract][Full Text] [Related]
20. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]